PHAGO

Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
PHAGO logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 5
Grant agreement number
115976

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
8 838 000
EFPIA in kind
9 092 496
Total Cost
17 930 496

Summary

Clumps of proteins in the brain called amyloid plaques are a hallmark of Alzheimer’s disease, and very often specialised immune cells cluster around these plaques. Recent research has shown that two genes involved in the immune system, TREM2 and CD33, appear to be involved in this immune response to Alzheimer’s disease and could therefore be targets for drugs. However, their exact role in the disease is still poorly understood. The PHAGO project aims to develop tools and methods to study the workings of these genes. The project results will therefore pave the way for the development of novel drugs that could tackle Alzheimer’s disease via this route.

Participants Show participants on map

EFPIA companies
  • Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany
  • Astrazeneca AB, Södertälje, Sweden
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • H. Lundbeck As, Valby, Denmark
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Orion Oyj, Espoo, Finland
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev, Bonn, Germany
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Goeteborgs Universitet, Gothenburg, Sweden
  • King'S College London, London, United Kingdom
  • Universitaetsklinikum Bonn, Bonn, Germany
  • University College London, London, United Kingdom
  • University of Cambridge, Cambridge, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Arttic, Paris, France
  • Axxam S.A, Bresso (Milan), Italy
  • Life And Brain GMBH, Bonn, Germany

CONTACT

Project leader
Dr. Andreas Ebneth
Janssen Pharmaceutica NV
AEBNETH[at]its.jnj.com
Project coordinator
Beate BECKER
UNIVERSITAETSKLINIKUM BONN
Beate.Becker[at]ukb.uni-bonn.de
E-mail address
info[at]phago.eu